Treatment of all GC-resistant organoid cells with the SCD1 inhibitor SSI423 would sensitize the cells to 5FU + CDDP chemotherapy (Fig. 5a, Supplementary Fig. 17a) and reduce tumor-initiating cell frequency (Fig. 5b, Supplementary Fig. 17b). This evidence concerns the gene SCD and neoplasm.